30 closest matches · ranked by relevance
Common Wart
Primary: The Primary Efficacy Endpoint is the Number of Subjects Whose Identified Common Warts Are Determined to be Clear on the PWA Scale (PWA=0) at Visit 10 (Day 60) — 40; 13…
Common Wart
Primary: Proportion of Subjects With Treatment Emergent AEs After Application of A-101 45% for the Treatment of Common Warts — 70; 116 Participants
Common Warts
Primary: Clinical Clearance of Warts — 13; 4; 2 # of warts
Common Wart
Primary: The Primary Efficacy Endpoint is the Number of Subjects Whose Identified Common Warts Are Determined to be Clear on the PWA Scale (PWA=0) at Visit 10 (Day 60) — 33; 8…
Common Wart
Primary: Mean Change in Physician's Wart Assessment Score From Baseline to Day 57 — -0.77; -0.23 score on a scale (PWA)
Cutaneous Common Warts
Primary: Difference in the Proportion of Subjects With Complete Clearance of All Treated Warts Between the Active and Vehicle at Week 18/End of Post-treatment Efficacy…
Common Wart
Primary: Physician's Wart Assessment — 1.52; 2.23 score on a scale
Cutaneous Common Warts
Primary: The Difference in the Proportion of Subjects With Complete Clearance of All Treated Warts Between the Active and Vehicle at Week 18/End of Post-treatment Efficacy…
Warts
Primary: Complete Regression of Wart — 12; 10 Participants
Warts · Plantar Wart · Common Wart
Primary: Diameter of the Wart — -0.12 cm
Warts · Warts Hand · Verruca
Primary: Percentage of Warts Resolved — 80.7; 73.1 percentage of warts resolved
Warts · Warts Hand · Verruca
Primary: Percentage of Verrucae Cleared — 67.6 percentage of verrucae clearance
Common Wart · Warts Hand · Warts
Primary: Cohort 1: Proportion of Subjects Exhibiting Complete Clearance of All Treatable Warts (Baseline and New) at the EOS Visit (Day 84) — 4 Participants
Warts
Primary: Number of Subjects With Complete Resolution of a Primary Injected Wart(s) at Any Treatment or Follow-up Visit — 16; 29; 31; 29 Participants — p=0.0329
Common Warts
Primary: Efficacy Based on Mean Change in Physician Wart Assessment Over Time — -0.38; -1.00; -0.44 units on a scale — p=0.555
Genital Warts · Perianal Warts
Primary: Efficacy: Complete Clearance of Baseline External Genital and Perianal Warts at or Before Week 12 — 2; 5; 2; 10 Participants
Verruca Viral
Primary: Efficacy of IL MMR and IL Vitamin D3 in Treatment of Warts — 25; 22; 2; 6 Participants
Verruca Vulgaris · Molluscum Contagiosum Skin Infection
Primary: Numbers of Lesions With no Response — 8; 9 lesions — p=0.534
Warts · Human Papilloma Virus
Primary: Number of Participants With Complete Resolution of Primary Injected Wart — 19 Participants
Warts · HPV
Primary: Number of Participants With Clinical Resolution of Injected Wart — 9; 1; 1 Participants
Papillomavirus Infections · Warts · Condylomata Acuminata
Primary: Difference in % Reduction in Wart Size Between Product A and Product B at Each Timepoint
Molluscum Contagiosum, Skin Disease
Primary: Patients Experiencing Complete Clearance of All Molluscum Lesions. — 1; 3 Participants
Human Papilloma Virus · Warts · Warts, Genital
Primary: Change in Wart Number — 0.5 warts
Genital Warts
Primary: Proportion of Subjects Achieving Complete Clearance of All Warts (Baseline and New) at the End of Study. — 0.248; 0.294; 0.09 proportion of participants
Genital Warts
Primary: Proportion of Subjects With Complete Clearance of All Warts (Both Presented at Baseline and Newly Emerged Warts) at End of Study — 0.191; 0.272; 0.103 participants
Plantar Warts
Primary: Lesion Assessment — 8.42; 9.14; 8.42; 8.71 millimeters — p=<0.001
Verruca, Warts
Primary: Size of Verrucae (Warts) — 2.333; 3.889 millimeters — p=0.383
External Genital Warts
Primary: Number of Participants With Complete Clearance, — 0; 0; 3; 5 participants
Papillomatosis · HIV Infections
Primary: Change in Total Oral Mucosal Area Covered by Warts. — 11; 2 participants — p=0.30
Genital Warts · Human Papilloma Virus
Primary: HPV DNA and HIV Status — 96; 19; 4; 5 participants